What This Regulatory News Could Mean for Merck
In late March, Merck's (NYSE: MRK) Keytruda, used in a chemotherapy pairing, received a positive opinion from the European Medicine Agency's Committee for Medical Products for Human Use (CHMP). The opinion recommended the approval of the duo to treat patients with recurrent or metastatic cervical cancer.
With a final decision expected in the second quarter of this year, regulatory approval for Keytruda could be just weeks away. So, let's dig into the phase 3 clinical results data for the Keytruda-chemotherapy combo and its annual sales potential for the pharma stock.
Cervical cancer is a type of cancer that begins in the cervix, which is the lower part of the uterus. Early-stage cervical cancer often has no symptoms, but advanced-stage cervical cancer can present with symptoms like pelvic pain.
Source Fool.com
